{
  "source": "NonFormulary-Fluticasone-propionate.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1423-3\nProgram Non-Formulary\nMedication Fluticasone propionate HFA*\nP&T Approval Date 12/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nFluticasone propionate HFA* is indicated for the maintenance treatment of asthma as prophylactic\ntherapy in adults and pediatric patients. Guidelines recommend the use of a spacer device based\non child’s age and capability. The preferred device in patients < 3 years of age is a spacer with\nface mask and for children aged 3-5 the preferred device is a spacer with mouthpiece. In addition,\nspacers remain essential for some elderly patients who are unable to utilize devices correctly.\nGuidelines from the American College of Gastroenterology and consensus recommendations from\nthe American Gastroenterological Association (AGA) Institute/North American Society of\nPediatric Gastroenterology, Hepatology, and Nutrition on the management of eosinophilic\nesophagitis recommend oral administration of inhalational corticosteroids (e.g., fluticasone,\nbudesonide) as first-line therapy in adults and children with eosinophilic esophagitis.\nClaims for patients less than 6 years of age will process automatically.\n2. Coverage Criteria:\nAuthorization\nA. Asthma\n1. Fluticasone propionate HFA* will be approved based on both of the following criteria:\na. Diagnosis of asthma\n-AND-\nb. One of the following:\n1) History of failure, contraindication or intolerance to both of the following:\na) Arnuity™ Ellipta®\nb) QVAR RediHaler®\n-OR-\n2) Patient requires a metered dose inhaler used with a spacer device due to one of the\nfollowing:\na) Physical dexterity\n© 2025 UnitedHealthcare Services Inc.\n1\nb) Inspiratory flow\nc) Cognitive status\nAuthorization will be issued for 12 months\nB. Eosinophilic Esophagitis\n1. Diagnosis of Eosinophilic Esophagitis\nAuthorization will be issued for 12 months\n*Fluticasone propionate HFA is typically excluded from coverage\n3. Additional Clinical Rules:\n• No",
    "hilic Esophagitis\n1. Diagnosis of Eosinophilic Esophagitis\nAuthorization will be issued for 12 months\n*Fluticasone propionate HFA is typically excluded from coverage\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Fluticasone HFA [package insert]. Mason, OH: Prasco Laboratories; May 2023\n2. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA).\n2024.\nProgram Non-Formulary – Fluticasone propionate HFA\nChange Control\nDate Change\n12/2023 New program.\n3/2024 Added eosinophilic esophagitis to criteria.\n3/2025 Annual review. Updated references.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}